{"id":961339,"date":"2026-05-12T07:35:18","date_gmt":"2026-05-12T11:35:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/"},"modified":"2026-05-12T07:35:18","modified_gmt":"2026-05-12T11:35:18","slug":"briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/","title":{"rendered":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Over 315 patients screened and over 230 patients enrolled in BriaCell\u2019s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer\u00a0<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Enrollment momentum continues with strong clinical site and patient interest<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Interim topline data expected in 2026<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell\u2019s Bria-IMT combination regimen continues under FDA Fast Track designation<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, May  12, 2026  (GLOBE NEWSWIRE) &#8212;  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates reporting topline data in 2026.<\/p>\n<p align=\"justify\">BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IzNgp2Md2dzNEcvZoFJ2M9BCpjyBYoHCqWfb9p2-dwz692hUxAxRqWSfr6cyLTG3JNKC4uRBqopDrkM--ahq9Ka039LXMawJ28KC98M14LzVTUiv3wqlAl3npVua6a7rEfgxgjN_9-EJFbRRGIYrUhT5QzFFnpyMMwSdt2WxOpF9XssOI1EFq1ux6vMhf_KX\" rel=\"nofollow\" target=\"_blank\">independent inclusion<\/a> of its Phase 3 clinical trial in <em>Nature Medicine\u2019s <\/em>article, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41fRwwM9gawuPvvrog6PKEAxa62USR1EpzzfJ4kfCPx9--JNPRq08dwoRFZFiSDdbXGZmlmTpAB1F-hf6XHPonA8NzPp79OtNXx5kS59HR7VZE0hk4-p30OeLfg7-IPANQQbLokyY_vZ68i3XvSpnHcQksgSuZKadZDWGTIjTurjVW1KolOkkxAflEWFUSk2\" rel=\"nofollow\" target=\"_blank\">\u201c<em>Eleven clinical trials that will shape medicine in 2026<\/em>\u201d<\/a>. The Phase 3 Bria-ABC study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician\u2019s choice of treatment in <u>a<\/u>dvanced\u00a0<u>b<\/u>reast\u00a0<u>c<\/u>ancer.<\/p>\n<p align=\"justify\">The interim analysis will be conducted after 144 patient events, defined as deaths, have occurred. Overall survival (OS) is the primary endpoint, and positive results could support full approval of Bria-IMT in patients with metastatic breast cancer. The Bria-IMT combination regimen has received FDA Fast Track designation.<\/p>\n<p align=\"justify\">\u201cSustained and new interest from world class institutions and their patients continues to drive remarkable patient engagement,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cWe remain on track to report the interim analysis in 2026 while continuing to enroll patients and advance preparations for potential commercialization, with the goal of bringing our novel immunotherapy regimen to patients with metastatic breast cancer as efficiently as possible.\u201d<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study, please visit ClinicalTrials.gov\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1ccx4Kj3xaAfvTfCuDgqwNRtnCmfyHZx1oDgswNS_zlBZ6Wbk0dlB3JRrKyK2dn2SWwyVbEgTqPrzPdWWti5GLo75a6wt_kJnFwanC0MDroIfOA9LWbna8V4H_eZ7merl9_MPc83SJAkrLXzgh20tDjTsGPewpC2RzocmUc-fmoAakDI9CJSKLwFwUSCKZHmO9Ux1iqAb7kjKgcQeDpmot2BWgEiDC43AAcBkQWj6QZCIQaGb2vrwMwDhyrHuI0xAKXJSdayEAe_jJ_nfOX5tdKcdqPUQzLM71xgJFweY6Y=\" rel=\"nofollow\" target=\"_blank\">NCT06072612\u00a0<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KCCXs5ipGB86GQmFTvbi7vXiAEzYe9Gzcb2od7czUIVwC1FqmWXXlH4Wo9l-WEauIDbkafwqNUsUT_oiXQ5FEnVPdqEYMGvgHlHBFjvm6QZvhnssNyFZ4McHEqVLjq99EW1trzfqhqA6C9QwlOiS0nuLBBhGsQ8CvRfaMtDSN-KA-dmqsgT84VEDFqKZHZKUyu3scpsHnFL2QB-eESz3Q6Lt9cIi_IMEtzu1rEuZVBp3ixu4GUAwrrrroIedkeosVngh7ZFALOvXSOO98lEehw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/\u00a0<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about ongoing patient enrollment in the pivotal Phase 3 clinical study of Bria\u2011IMT, the expected timing of interim analysis and topline data readout, and the potential for full approval and marketing authorization of the Bria\u2011IMT combination regimen, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eIgtVz3ldDdfqmk3V4eqN_9rBYwWwgbVJ4vq2Dg5iQhcFxPgGMUsNDnLviBQmFqDwzKfXXZXNbTz7YQWIVbQP88YrDOxwtYPY83ngsd7r8A=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca\u00a0<\/strong><\/a>and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eIgtVz3ldDdfqmk3V4eqNzJW3ZPpWkcpN3uuo4jd00yljeUj-AQLeHmQQu0AN8nDUmfKTDOhF6YP7y-BWp1hYw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"justify\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C86r0nLhNSF5p_e_Ksq1Y4dkx0Zl9eNIluSXAjYYTruHef2a2rK99oZB-H8MNstM6lJsuuwhwLlS2nkZjXiUF3BiN_mxg3NRDM4Www8cck0YVZxPdo8hBiFj0MTOOug4FsjDuMCKyyEnJh2GYg7N8nDfWh-2-ngEWSYUjfrU7rwQSFF9jl3gtvIHMyuzEg8UB5zqjV5zz8KWlwAmxb1f4YphP-VeWZC4aZhmJXpWUL-G-WDsKh0KHNVPCBMaQy1jQGYMBZepe0_nMHToAzsHrA==\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MjPKSPpnUipVQk3CZHXvK0OBHNRxZKndM3pu-0YpAFATq0fx7J2ixnIgdCn3Im-R5YNCXJU1ulpyn7H94roDh8ti-1bz5Uiyw_U4HDm3AXhckVsOhfH2VXmdHGKrBbNu2Tx0UwWwVxZRUr8EBzrtQ10bEi4E0I3tPkAWW3HGi-80RWUD6cOnB4VfSZVn5edXcX1UeDc21LP5xdtcmiYNWQ2jCBsTzeNLhtdZgR5IlAOCVpkOY4MsjviSTzg7aWl6OxZp_Bb3CJUyE4g_MMOzoQ==\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGIzZDA3Y2QtNjQ0NC00ODA3LTkyNjctOTY4OGE0Y2RiNjZkLTExMDIyMjktMjAyNi0wNS0xMi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Over 315 patients screened and over 230 patients enrolled in BriaCell\u2019s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer\u00a0 Enrollment momentum continues with strong clinical site and patient interest Interim topline data expected in 2026 Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer BriaCell\u2019s Bria-IMT combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Over 315 patients screened and over 230 patients enrolled in BriaCell\u2019s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer\u00a0 Enrollment momentum continues with strong clinical site and patient interest Interim topline data expected in 2026 Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer BriaCell\u2019s Bria-IMT combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates &hellip; Continue reading &quot;BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T11:35:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients\",\"datePublished\":\"2026-05-12T11:35:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/\"},\"wordCount\":684,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/\",\"name\":\"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\",\"datePublished\":\"2026-05-12T11:35:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk","og_description":"Over 315 patients screened and over 230 patients enrolled in BriaCell\u2019s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer\u00a0 Enrollment momentum continues with strong clinical site and patient interest Interim topline data expected in 2026 Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer BriaCell\u2019s Bria-IMT combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates &hellip; Continue reading \"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T11:35:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients","datePublished":"2026-05-12T11:35:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/"},"wordCount":684,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/","name":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=","datePublished":"2026-05-12T11:35:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzk3NyM3NTk2Nzc5IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-3-bria-imt-study-enrollment-surpasses-230-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Phase 3 Bria-IMT\u2122 Study Enrollment Surpasses 230 Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}